The virology and clinical effects of peramivir on influenza virus infections in high-risk patients or patients with severe symptoms:an open-label, non-randomized, multi-centre study.

The virology and clinical effects of peramivir on influenza virus infections in high-risk patients or patients with severe symptoms:an open-label, non-randomized, multi-centre study. - The virology and clinical effects of peramivir on influenza virus infections.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007320

Enrollment

Registered

2012-02-21

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza virus infections.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with informed consent. 2) Age: over 20 years. 3) Patients of the following high-risk factors under treatment: Chronic heart, lung, kidney, liver, nerve, blood diseases or diabetes or weakened immune systems. Age 65 or older. 4) To get nasal/throat swabs in fluid for virology. 5) Patient who must be sent to hospital. 6) Gender: Male or female.

Exclusion criteria

Exclusion criteria: 1) History of hypersensitivity, allergy or serious adverse drug event caused by neuraminidase inhibitors. 2) Pregnant women. 3) Patients who are deemed to be inappropriate by the investigator.

Design outcomes

Primary

Measure	Time frame
Ratio of influenza virus-positive patients.	—

Secondary

Measure	Time frame
Virus mutation after treatment of peramivir. Time to return to normal body temperature. Duration of influenza symptoms.	—

Countries

Japan

Outcome results